勃林格殷格翰的思力华疗效怎么样？

(Respimat) is a new drug that has been launched in recent years. Its soft mist inhaler is a new generation of propellant-free inhaler. In this type of inhalation device, inhalable droplets are produced from aqueous solutions. The size and speed of the droplets allow the drug aerosol to be deposited into the patient's lungs, bringing good inhalation effects. It is used by many patients with chronic obstructive pulmonary disease (COPD). So, how effective is Boehringer Ingelheim’s Spirax?

In order to explore the efficacy of Seretide combined with Seriva in the treatment of chronic obstructive pulmonary disease (COPD), a domestic study selected 300 patients with chronic obstructive pulmonary disease as subjects. The random number table was divided into a control group (n=150) and an observation group (n=150). The control group was treated only with Seretide, while the observation group was treated with Seretide combined with Slivar. After 1 month of treatment, the patient's therapeutic effect was evaluated. The blood gas indicators and serum inflammatory factor levels, patient satisfaction and post-treatment adverse reactions were compared between the two groups.

Results: In this study, there was no statistically significant difference between the two groups of patients before and after treatment (p>0.05). The blood gas indicators and serum inflammatory factor levels in the control group were better than those in the control group (P<0.05). The patient satisfaction in the observation group was significantly higher than that in the control group (P<0.05). The improvement in the observation group was significantly better than that in the control group (P<0.05). It can be seen that applying the treatment method of Seretide combined with Slivar to the treatment of chronic obstructive pulmonary disease can improve the lung function of patients, effectively reduce the incidence of chronic obstructive pulmonary disease in patients, and the patient satisfaction is high, so it is worthy of promotion and application.

Boehringer Ingelheim has always adhered to the tradition of "innovation demonstrates value and R&D drives growth", and has finally extended from the Rhine River in Germany to more than 40 countries and regions around the world. In recent years, it has continuously injected new products into the Chinese market, covering cardiovascular, central nervous system, etc. The industry and market have given the company various reputations and recognitions. Its products have reliable efficacy and are worthy of patients' favor.

Recommended hot articles: /newsDetail/92340.html